Earnings Preview: What to Expect From Amcor's Report

Amcor plc (AMCR), headquartered in Zurich, Switzerland, develops, produces, and sells packaging for food, beverage, pharmaceutical, medical, home and personal care, and other products. Valued at $13.6 billion by market cap, the company, through its flexible and rigid packaging, specialty cartons, closures, and services, helps leading companies protect their products and differentiate their brands. The global consumer and healthcare packaging giant is expected to announce its fiscal second-quarter earnings for 2025 on Tuesday, Feb. 4.

Ahead of the event, analysts expect AMCR to report a profit of $0.16 per share on a diluted basis, unchanged from the year-ago quarter. The company has beat or matched Wall Street’s EPS estimates in its last four quarterly reports. 

For the full year, analysts expect AMCR to report EPS of $0.74, up 5.7% from $0.70 in fiscal 2024. Its EPS is expected to rise 6.8% year over year to $0.79 in fiscal 2026. 

www.barchart.com

AMCR stock has underperformed the S&P 500’s ($SPX21.8% gains over the past 52 weeks, with shares down 3.6% during this period. Similarly, it underperformed the Consumer Discretionary Select Sector SPDR Fund’s (XLY)25.3% gains over the same time frame.

www.barchart.com

AMCR's performance has been affected by reduced pass-through costs and negative foreign exchange effects. Additionally, higher SG&A expenses and a significant rise in net debt have raised concerns about potential cost challenges and financial risks among investors.

On Nov. 1, AMCR shares closed down more than 7% after reporting its Q1 results. Its adjusted EPS of $0.16 matched Wall Street expectations. The company’s revenue stood at $3.4 billion, down 2.6% year over year. Amcor expects full-year adjusted EPS in the range of $0.72 to $0.76.

Analysts’ consensus opinion on AMCR stock is moderately bullish, with a “Moderate Buy” rating overall. Out of 10 analysts covering the stock, six advise a “Strong Buy” rating, and four give a “Hold.” AMCR’s average analyst price target is $11.57, indicating a potential upside of 23% from the current levels.

On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. More news from Barchart

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.